ELDN - CIK 0001404281
The table below shows Eledon Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$22.61M | -$16.06M | -$8.74M | -$9.92M | -$8.16M | -$5.17M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $5.96M | $3.89M | $9.78M | - | - | - |
| Dividends paid | - | - | - | - | - | - |
Eledon Pharmaceuticals, Inc. reported operating cash flow of -$62.34M for fiscal year 2025. That is down 31.9% from -$47.27M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$14.94M (FY 2017) to -$62.34M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | $115.00K | $1.00K | - | - | -$450.00K |